Mi SciELO
Servicios Personalizados
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista Cubana de Medicina
versión On-line ISSN 1561-302X
Resumen
ELZAURDIN MORA, Rubén Alexander y LARA FERNANDEZ, Noralys. Nimotuzumab in the treatment of a patient with anaplastic astrocytoma. Rev cubana med [online]. 2019, vol.58, n.4 Epub 08-Jul-2020. ISSN 1561-302X.
Introduction:
Nimotuzumab is an IgG1 isotype immunoglobin, obtained by recombinant DNA technology. Life expectancy is approximately one month in children with recurrent brain tumors, refractory to treatments to surgery, radiotherapy and chemotherapy. Survival reaches 44.5 months when using Nimotuzumab.
Objectives:
To report the clinical case of a patient diagnosed with anaplastic astrocytoma who received concurrent oncospecific treatment with Nimotuzumab.
Case report:
This paper describes the diagnosis, treatment and evolution of a 31-year-old male patient with neoplasm of the central nervous system (Anaplastic astrocytoma). He received the therapeutic combination of surgery, radiotherapy and monoclonal antibodies, achieving a survival of 39 months.
Conclusions:
The adding the monoclonal antibody to the standard treatment of brain tumors increased patient survival, making it a safe, advantageous and feasible therapeutic alternative as part of conventional treatment in healthcare conditions.
Palabras clave : central nervous system; high-grade gliomas; nimotuzumab; monoclonal antibody.